Biopharmaceutical company Zavante Therapeutics Inc revealed on Thursday the launch of a Clinical Trial Agreement to evaluate its investigational antibiotic ZOLYD (fosfomycin for injection, also known as ZTI-01) for bacterial pneumonia in partnership with the National Institute of Allergy and Infectious Disease (NIAID).
The company said the clinical trial is designed to assess the intrapulmonary penetration and pharmacokinetics of ZOLYD to support future development for US patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) infections, with a combined mortality rate of up to 33%.
In conjunction, the US FDA has granted Fast Track and Qualified Infectious Disease Product (QIDP) designations to ZOLYD for both indications, HABP and VABP.
According to the partnership, ZOLYD is an investigational, first-in-class injectable epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most multi-drug resistant strains that are of particular concern to public health. ZOLYD has a differentiated mechanism of action that acts at an earlier step in cell wall synthesis inhibition, providing activity against pathogens that are often resistant to other classes of antibiotics.
NIAID, part of the National Institutes of Health, plans to initiate a Phase 1 trial in the fourth quarter of 2017 to determine the intrapulmonary pharmacokinetics of ZOLYD after multiple doses in 36 healthy subjects. This trial will be conducted by the Vaccine and Treatment Evaluation Unit (VTEU) at Duke University (Contract #HHSN272201300017I). Zavante will supply the investigational product that will be tested in this trial.
Under the trial, the companies will measure ZOLYD's pulmonary penetration by assessing drug concentrations in the lining of subjects' bronchial pathways. The NIAID-supported trial will provide additional data regarding the safety and tolerability of a contemporary dosing regimen (six grams every eight hours) to support further evaluations in the intended patient populations.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer